Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow long you need to be on Wegovy depends on how your body responds, but most people stay on it for at least a year — and many continue beyond that. Wegovy is a prescription-only medicine requiring ongoing clinical assessment, not a short course you finish and move on from. The honest answer: for most people, the question shifts from when do I stop to is this still working, and is it still right for me. Here's what the evidence actually says.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
That question is one our prescribers hear most weeks. You've got through the early nausea, you're on a higher dose, and the weight is moving, but nobody's told you how long this actually goes on for. It's a reasonable thing to want clarity on, and the absence of a clear answer can feel unsettling.
The short version: Wegovy isn't designed like a course of antibiotics. The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and found an average weight reduction of around 15% at the 2.4mg dose. Crucially, participants who stopped semaglutide regained most of that weight within a year. The medicine works while you take it; it doesn't permanently reset your appetite biology after a fixed number of months. That shapes how long most people end up staying on it.
For people accessing Wegovy through the full Wegovy treatment overview, it helps to understand this from the outset rather than arrive at month nine expecting a taper conversation that isn't coming.
You may have read that NICE recommends semaglutide for a maximum of two years. That's accurate, but the context matters. NICE's appraisal of semaglutide (TA875) applies specifically to NHS access through specialist weight management services, where the two-year cap is a commissioning boundary, not a clinical verdict on what's safe or appropriate beyond that point. NICE also advises that treatment should be reviewed if less than 5% weight loss has occurred after six months at the maintenance dose.
Private treatment follows the licensed indication in the SmPC rather than the NICE commissioning guidance. The medicine's UK licence doesn't carry an absolute time ceiling; duration is a clinical decision based on continued benefit, tolerability, and your overall health picture. That's exactly the kind of ongoing review that should happen with every repeat, the question of how long you can stay on Wegovy is explored in more detail separately.
What both routes agree on: if the medicine isn't producing meaningful weight loss, continuing it isn't appropriate. The prescriber's job (not yours) is to assess that regularly.
One reason people feel unsure about timelines is that the first few months aren't representative. The standard semaglutide titration moves from 0.25mg through 0.5mg, 1mg, and 1.7mg before reaching 2.4mg maintenance, roughly 16 to 20 weeks of gradual increases. The starter doses are about giving your digestive system time to adjust, not about maximum effect. Expecting significant weight change during titration is a setup for disappointment.
Meaningful loss typically becomes consistent from around week 12 and accelerates through months four to twelve. The curve flattens after that, which is normal and doesn't mean the medicine has stopped working. It means you've found your new setpoint. How quickly Wegovy produces noticeable results is a separate question worth reading alongside this one if you're still in the early stages.
If you're considering costs alongside duration, the UK price context for Wegovy is worth understanding before you commit to what could be a multi-year course of treatment.
Stopping Wegovy is something to plan with your prescriber rather than decide unilaterally. The trial evidence is clear: in participants who discontinued after 68 weeks of treatment, roughly two-thirds of lost weight returned within a year. That isn't a failure of willpower; semaglutide reduces appetite by acting on GLP-1 receptors, and when the medicine is gone, that signal goes with it.
That said, stopping isn't always the wrong call. If you've made substantial, durable lifestyle changes alongside treatment, if your weight-related health conditions have resolved, or if the medicine is no longer producing benefit, your prescriber may agree that the evidence supports tapering off. Our guide to how long you need to take Wegovy walks through the clinical factors that typically inform that conversation. The conversation should happen with a clinician who knows your case, not based on a fixed number of months. You can read more about how long you have to stay on Wegovy to get a sense of the factors involved.
Duration is ultimately a clinical decision, made between you and a prescriber who has the full picture. If you haven't had that conversation recently, or you're still working out whether Wegovy is right for you at all, check your eligibility with our clinical team, a real prescriber reviews every consultation, no algorithm involved.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.